Progression-Free Survival Prediction Model Based on AI-Enhanced Dynamic Radiomics for Personalized EGFR-TKI Treatment Monitoring Patients With Lung Adenocarcinoma.

ABSTRACT:

Background and objective

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment for patients with advanced lung adenocarcinoma (LUAD) with EGFR mutations. However, treatment effectiveness varies widely among individuals, and effective models to predict treatment response are lacking. This study aims to establish a progression-free survival (PFS) prediction model based on dynamic changes in pre- and post-treatment CT scans combined with patients' clinical features.

Methods

A total of 183 patients with advanced LUAD who received first-line treatment at Peking University Third Hospital from January 2013 to December 2022 were enrolled. A 3D-UNet model was fine-tuned using data from 405 patients with non-small cell lung cance

SUBMITTER: Liu Y 

PROVIDER: S-EPMC11926440 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature